Clinical trials: Heart Failure with Reduced Ejection Fraction HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Telemonitoring of HFrEF Patients
The aim of this study is to find out whether remote health monitoring can help people with chronic heart failure. For 3 months, some patients use a SiDLY CARE PRO electronic wristband.
- Trial name
- NCT07835490
- Testing
- Telemonitoring wristband
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Lodz
Heart Failure, Overweight and Obesity
Mobile Applet for Weight Management in Obese Heart Failure Patients
The objective of this clinical trial is to investigate the effect of weight reduction through a diet management application and an intelligent weight scale on a composite cardiovascular endpoint in obese patients with heart…
- Conditions
- Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
- Trial name
- IDEAL-HF (NCT06455878)
- Testing
- Full usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scale
- Where
- 26 sites in China
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Heart Health Research Center
Heart Failure With Reduced Ejection Fraction HFrEF
Translational and Clinical Aspects of Metabolic, Anabolic and Endothelial Dysfunction in Heart Failure
In patients with HF cardiac output, metabolism and endothelial function will be studied during and after treatment with ghrelin infusion
- Trial name
- MetAnEnd-HF (NCT05277415)
- Testing
- Ghrelin
- Volunteers
- 31 people
- Sponsor
- Lars Lund
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of…
- Trial name
- ASTRAAS-HF (NCT04836182)
- Testing
- IONIS-AGT-LRx
- Where
- 19 sites in United States, Hungary and 1 more
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Heart Failure With Reduced Ejection Fraction
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes.
- Trial name
- LYRIC-HF (NCT07695090)
- Testing
- Lumacaftor 200 MG
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Qanatpharma AG
Heart Failure With Reduced Ejection Fraction
Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure
Sacubitril-Valsartan reduced heart failure hospitalizations and cardiovascular mortality compared to enelapril in chronic heart failure. Furthermore, quality of life is improved.
- Trial name
- ARNI-PVA (NCT04498780)
- Testing
- Sacubitril-Valsartan
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- University of Leipzig
Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
This multicentre, prospective, single-arm cohort study will evaluate the real-world effectiveness and safety of Savagen, an NPRA-approved generic sacubitril/valsartan, in Malaysian adults aged 18 to 70 years with heart failure…
- Trial name
- NCT07907640
- Testing
- Savagen (sacubitril/valsartan)
- Where
- 2 sites in Malaysia
- Volunteers
- 80 people
- Sponsor
- Sunway University
Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan
Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)
The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed…
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence
- Trial name
- NCT06900803
- Testing
- interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Heart Failure With Reduced Ejection Fraction, Obesity
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
The benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss, Chronic Heart Failure
- Trial name
- FIT-HF (NCT06423599)
- Testing
- Semaglutide Injectable Product, Calorie-restricted diet
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Jens D Hove, MD,PHD
Cardiac Failure, Systolic Heart Failure
Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure
In general, anemia is associated with a greater presence of HF symptoms, worsening NYHA functional class, higher rate of hospitalization for heart failure, and reduced survival.
- Conditions
- Cardiac Failure, Systolic Heart Failure, Heart Failure, Systolic
- Trial name
- IronHeart (NCT03871699)
- Testing
- Ferric carboxymaltose
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Moinhos de Vento
Physical Activity, Heart Failure
WHISH-2-Prevent Heart Failure
The WHISH-2-Prevent Heart Failure (HF) study is an ancillary study to the Women's Health Initiative Strong and Healthy (WHISH) exercise pragmatic trial.
- Conditions
- Physical Activity, Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03099889
- Testing
- Physical Activity
- Where
- United States
- Volunteers
- 49,936 people, healthy volunteers welcome
- Sponsor
- Memorial Hospital of Rhode Island
Heart Failure
REDUCE LAP-HFREF TRIAL
The objective of this pilot study is to evaluate the safety and performance of implanting the IASD® System II in Heart Failure patients with reduced ejection fraction and elevated left sided filling pressures, who remain…
- Trial name
- NCT03093961
- Testing
- IASD implant
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Corvia Medical
Heart Failure With Reduced Ejection Fraction
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF).
- Trial name
- IICAPTAIN-HF (NCT06526988)
- Testing
- EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert
- Where
- 5 sites in United States
- Volunteers
- 2,200 people
- Sponsor
- University of Colorado, Denver
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
PCI With GDMT Versus GDMT Alone for Patients With Ischemic Cardiomyopathy and Reduced LVEF
To evaluate whether percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) combined with guideline-directed medical therapy (GDMT), compared to GDMT alone, reduces the time to first occurrence of…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease, Stable GDMT
- Trial name
- PCI-GULF (NCT07349979)
- Testing
- Percutaneous coronary intervention, Guideline-directed medical therapy
- Where
- China
- Volunteers
- 1,154 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Heart Failure, Mortality
The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF
This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice.
- Trial name
- PARADE-HF (NCT05329727)
- Testing
- Angiotensin receptor neprilysin inhibitor (ARNI), Renin-Angiotensin System Inhibitor (RAS inhibitor)
- Where
- South Korea
- Volunteers
- 1,000,000 people
- Sponsor
- Wonju Severance Christian Hospital
Heart Failure, Systolic
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
This clinical study will utilize allogenic bone marrow-derived culture-expanded MSC that are expanded from mesenchymal stem cells and delivered using the investigational Helix transendocardial delivery catheter as a therapy for…
- Trial name
- CardiALLO (NCT05925608)
- Testing
- CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs), Diagnostic Catheterization
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- BioCardia, Inc.
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
This is an observational study in which data from people in China with chronic heart failure with reduced ejection fraction (HFrEF) who will be receiving vericiguat treatment are collected.
- Trial name
- VERI-China (NCT05728502)
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of Care (SoC)
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Hyperkalaemia, Heart Failure with Reduced Ejection Fraction
Hyperkalaemia and Its Impact on Therapy with RAASi
Renin-angiotensin-aldosterone system inhibitors (RAASi) have transformed prognosis of patients with heart failure with reduced ejection fraction, diabetic nephropathy and chronic kidney disease.
- Conditions
- Hyperkalaemia, Heart Failure with Reduced Ejection Fraction, Left Ventricular Systolic Dysfunction
- Trial name
- REVIEW (NCT04249648)
- Where
- United Kingdom
- Volunteers
- 651 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Type 2 Diabetes Mellitus (T2DM), Chronic Heart Failure (CHF)
Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
Evaluating the safety and efficacy of glimepiride in patients with type 2 diabetes and chronic heart failure with reduced ejection fraction--a multicenter randomized controlled study.
- Trial name
- GLID-HF (NCT07288749)
- Testing
- Glimepiride (oral)
- Where
- China
- Volunteers
- 1,484 people
- Sponsor
- Tongji Hospital
Chronic Heart Failure
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable…
- Trial name
- POWER-HF (NCT06017609)
- Testing
- JTT-861 Capsules
- Where
- 75 sites in United States, Bulgaria and 4 more
- Volunteers
- 314 people
- Sponsor
- Shionogi Inc.